Hennion & Walsh Asset Management, Inc. Immunity Bio, Inc. Transaction History
Hennion & Walsh Asset Management, Inc.
- $2.59 Billion
- Q3 2025
A detailed history of Hennion & Walsh Asset Management, Inc. transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Hennion & Walsh Asset Management, Inc. holds 306,784 shares of IBRX stock, worth $638,110. This represents 0.03% of its overall portfolio holdings.
Number of Shares
306,784
Previous 180,521
69.94%
Holding current value
$638,110
Previous $476,000
58.4%
% of portfolio
0.03%
Previous 0.02%
Shares
2 transactions
Others Institutions Holding IBRX
# of Institutions
297Shares Held
137MCall Options Held
2.59MPut Options Held
3.35M-
Vanguard Group Inc Valley Forge, PA27.7MShares$57.5 Million0.0% of portfolio
-
Jane Street Group, LLC New York, NY12.8MShares$26.7 Million0.01% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$23.8 Million0.0% of portfolio
-
State Street Corp Boston, MA11.3MShares$23.5 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA6.89MShares$14.3 Million0.0% of portfolio
About ImmunityBio, Inc.
- Ticker IBRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 400,304,000
- Market Cap $833M
- Description
- ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...